Main Organiser

Julius Centre University of Malaya

Co-organiser

Department of Social and Preventive Medicine, Faculty of Medicine, University of Malay

Supported by

University of Malaya

PRACTICE OF PRESCRIBING ADJUVANT CHEMOTHERAPY FOR STAGE II COLORECTAL CANCER PATIENTS IN UMMC FROM 2007 TO 2010

Author

LUI S.A., LAW C.W., HO G.F.

Institution

University of Malaya Medical Centre

Abstract

Objectives: To study the practice of prescribing adjuvant chemotherapy for stage II colorectal (CRC) patients in UMMC.

Methods: All the medical records of stage II CRC patients treated between 2007-2010 were retrieved. We recorded the indications and side effects of adjuvant chemotherapy.

Results: 87 patients with stage 2 disease received surgery during this period. Postoperatively, 72 (82.8%) were referred to Oncology. Out of the patients referred, 60 patients (83.3%) were offered adjuvant chemotherapy, and 42 (58.3%) went on to receive it. 28 of the 60 patients (46.7%) offered chemotherapy did not have any poor histological features and/or high-risk presentation. The main reason chemotherapy was offered was because of inadequate lymph nodes harvested (24 patients). Chemotherapy was associated with the following side effects: haematological derangements (28.6%), dermatological symptoms (28.6%), diarrhea (26.2%), diarrhea (26.2%), peripheral numbness (11.9%), vomiting (11.9%) asthenia (7.14%) anorexia (7.14%) and neutropenia sepsis (2.38%).

Conclusion: Current ASCO and NCCN guidelines are against the routine use of adjuvant therapy for low-risk stage II colon cancer patients. This study showed that many low-risk stage II CRC patient received adjuvant chemo because of inadequate lymph node harvested; hence additional methods to improve the lymph nodes harvesting rate should be pursued.